Ashana Puri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashana Puri has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Akeemat O. Tijani
Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN 37614, USA
9 shared publicationsAkeemat Tijani
Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN 37614, USA
6 shared publicationsDorcas Frempong
Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, USA
3 shared publicationsGabrielle Verana
Department of Pharmaceutical Sciences, Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, Tennessee 37614, United States
3 shared publicationsMaria J. Peláez
Mathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, TX 77030, USA
3 shared publicationsPrashant Dogra
Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, USA
3 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 398, 115214
Transdermal delivery of biologics
- 28 July 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 398, 115214
Open AccessTransdermal delivery of biologics
- 12 July 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (2) , 598-612
Microneedle patch-based transnasal delivery of naloxone
This study evaluates dissolving microneedle (MN) patches for naloxone (NAL) delivery via the transnasal route, addressing limitations seen with transdermal application of same and the limitations of conventional NAL intranasal sprays, which often require frequent redosing, particularly for long-acting opioids like fentanyl. MN patches composed of polyvinylpyrrolidone (PVP) and PVP/Chitosan were tested on porcine nasal mucosa. PVP patches achieved significantly higher 1-h cumulative permeation (7295.12 ± 2585.17 µg/cm²) compared to transdermal application (103 ± 15.18 µg/cm², p < 0.05). Over 24 h, cumulative permeation reached 13,113.20 ± 597.39 µg/cm² transnasally versus 4112.89 ± 773.40 µg/cm² transdermally (p < 0.05). Chitosan-PVP MN patches improved bioadhesion and demonstrated high 1-h cumulative permeation (3800.19 ± 940.51 µg/cm²). PVP MN patches with drug-loaded tips (MN/TO, where TO implies “tip only”) delivered 933.90 ± 161.60 µg/cm² in 1 h that was also a remarkable increase over transdermal permeation (p < 0.05) but had lower 24 h permeation. Similar observation was seen with the PVP/Chitosan variant with drug loaded in just MN tips indicating that sustained delivery requires drug in both the tips and base. To further refine patch designs, a mathematical modeling framework was employed to simulate drug dissolution, permeation dynamics, and plasma concentration kinetics. Simulations demonstrated that optimized patches could achieve plasma profiles comparable to intranasal and intramuscular administration, while minimizing drug dose and patch size. Increasing drug concentration from 50 to 60 mg/ml decreased permeation, likely due to drug crystallization. Overall, MN patches showed consistent, sustained NAL delivery, providing an alternative option for efficient opioid overdose treatment.
- 12 July 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (2) , 598-612
Microneedle patch-based transnasal delivery of naloxone
This study evaluates dissolving microneedle (MN) patches for naloxone (NAL) delivery via the transnasal route, addressing limitations seen with transdermal application of same and the limitations of conventional NAL intranasal sprays, which often require frequent redosing, particularly for long-acting opioids like fentanyl. MN patches composed of polyvinylpyrrolidone (PVP) and PVP/Chitosan were tested on porcine nasal mucosa. PVP patches achieved significantly higher 1-h cumulative permeation (7295.12 ± 2585.17 µg/cm²) compared to transdermal application (103 ± 15.18 µg/cm², p < 0.05). Over 24 h, cumulative permeation reached 13,113.20 ± 597.39 µg/cm² transnasally versus 4112.89 ± 773.40 µg/cm² transdermally (p < 0.05). Chitosan-PVP MN patches improved bioadhesion and demonstrated high 1-h cumulative permeation (3800.19 ± 940.51 µg/cm²). PVP MN patches with drug-loaded tips (MN/TO, where TO implies “tip only”) delivered 933.90 ± 161.60 µg/cm² in 1 h that was also a remarkable increase over transdermal permeation (p < 0.05) but had lower 24 h permeation. Similar observation was seen with the PVP/Chitosan variant with drug loaded in just MN tips indicating that sustained delivery requires drug in both the tips and base. To further refine patch designs, a mathematical modeling framework was employed to simulate drug dissolution, permeation dynamics, and plasma concentration kinetics. Simulations demonstrated that optimized patches could achieve plasma profiles comparable to intranasal and intramuscular administration, while minimizing drug dose and patch size. Increasing drug concentration from 50 to 60 mg/ml decreased permeation, likely due to drug crystallization. Overall, MN patches showed consistent, sustained NAL delivery, providing an alternative option for efficient opioid overdose treatment.
- 31 May 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 660, 124289
Iontophoresis-coupled rapidly dissolving polymeric microneedle patch of naloxone for its enhanced transdermal delivery
- 31 May 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 660, 124289
Iontophoresis-coupled rapidly dissolving polymeric microneedle patch of naloxone for its enhanced transdermal delivery
- 25 April 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (5) , 2118-2147
Nanocarrier-Integrated Microneedles: Divulging the Potential of Novel Frontiers for Fostering the Management of Skin Ailments
The various kinds of nanocarriers (NCs) have been explored for the delivery of therapeutics designed for the management of skin manifestations. The NCs are considered as one of the promising approaches for the skin delivery of therapeutics attributable to sustained release and enhanced skin penetration. Despite the extensive applications of the NCs, the challenges in their delivery via skin barrier (majorly stratum corneum) have persisted. To overcome all the challenges associated with the delivery of NCs, the microneedle (MN) technology has emerged as a beacon of hope. Programmable drug release, being painless, and its minimally invasive nature make it an intriguing strategy to circumvent the multiple challenges associated with the various drug delivery systems. The integration of positive traits of NCs and MNs boosts therapeutic effectiveness by evading stratum corneum, facilitating the delivery of NCs through the skin and enhancing their targeted delivery. This review discusses the barrier function of skin, the importance of MNs, the types of MNs, and the superiority of NC-loaded MNs. We highlighted the applications of NC-integrated MNs for the management of various skin ailments, combinational drug delivery, active targeting, in vivo imaging, and as theranostics. The clinical trials, patent portfolio, and marketed products of drug/NC-integrated MNs are covered. Finally, regulatory hurdles toward benchtop-to-bedside translation, along with promising prospects needed to scale up NC-integrated MN technology, have been deliberated. The current review is anticipated to deliver thoughtful visions to researchers, clinicians, and formulation scientists for the successful development of the MN-technology-based product by carefully optimizing all the formulation variables.
- 25 April 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (5) , 2118-2147
Nanocarrier-Integrated Microneedles: Divulging the Potential of Novel Frontiers for Fostering the Management of Skin Ailments
The various kinds of nanocarriers (NCs) have been explored for the delivery of therapeutics designed for the management of skin manifestations. The NCs are considered as one of the promising approaches for the skin delivery of therapeutics attributable to sustained release and enhanced skin penetration. Despite the extensive applications of the NCs, the challenges in their delivery via skin barrier (majorly stratum corneum) have persisted. To overcome all the challenges associated with the delivery of NCs, the microneedle (MN) technology has emerged as a beacon of hope. Programmable drug release, being painless, and its minimally invasive nature make it an intriguing strategy to circumvent the multiple challenges associated with the various drug delivery systems. The integration of positive traits of NCs and MNs boosts therapeutic effectiveness by evading stratum corneum, facilitating the delivery of NCs through the skin and enhancing their targeted delivery. This review discusses the barrier function of skin, the importance of MNs, the types of MNs, and the superiority of NC-loaded MNs. We highlighted the applications of NC-integrated MNs for the management of various skin ailments, combinational drug delivery, active targeting, in vivo imaging, and as theranostics. The clinical trials, patent portfolio, and marketed products of drug/NC-integrated MNs are covered. Finally, regulatory hurdles toward benchtop-to-bedside translation, along with promising prospects needed to scale up NC-integrated MN technology, have been deliberated. The current review is anticipated to deliver thoughtful visions to researchers, clinicians, and formulation scientists for the successful development of the MN-technology-based product by carefully optimizing all the formulation variables.
- 6 April 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 369, 475-492
Adjuvants in cutaneous vaccination: A comprehensive analysis
- 6 April 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 369, 475-492
Adjuvants in cutaneous vaccination: A comprehensive analysis
- 2 November 2023
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 24 (8) , 1-14
Effects of Sodium Salts of Fatty Acids and Their Derivatives on Skin Permeation of Cromolyn Sodium
Atopic dermatitis is a chronic inflammatory disorder with rising prevalence. The safety concerns over usually used steroids are driving the need for develo
- 2 November 2023
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 24 (8) , 1-14
Effects of Sodium Salts of Fatty Acids and Their Derivatives on Skin Permeation of Cromolyn Sodium
Atopic dermatitis is a chronic inflammatory disorder with rising prevalence. The safety concerns over usually used steroids are driving the need for develo
- 28 August 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 644, 123352
Nanosuspension-based microneedle skin patch of baclofen for sustained management of multiple sclerosis-related spasticity
- 28 August 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 644, 123352
Nanosuspension-based microneedle skin patch of baclofen for sustained management of multiple sclerosis-related spasticity
- 17 June 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 642, 123159
Transdermal delivery of naloxone hydrochloride using minimally invasive physical ablation techniques
- 17 June 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 642, 123159
Transdermal delivery of naloxone hydrochloride using minimally invasive physical ablation techniques
- 1 February 2023
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 24 (2) , 1-11
Dermaplaning for Transdermal Drug Permeation Enhancement: A Qualitative and Quantitative Assessment
In this study, we sought to investigate the effect of dermaplaning, a popular cosmeceutical skin rejuvenation technique on the permeation of drugs. Baclofe
- 1 February 2023
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 24 (2) , 1-11
Dermaplaning for Transdermal Drug Permeation Enhancement: A Qualitative and Quantitative Assessment
In this study, we sought to investigate the effect of dermaplaning, a popular cosmeceutical skin rejuvenation technique on the permeation of drugs. Baclofe
- 25 July 2022
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 13 (1) , 320-338
Mechanistic modeling-guided optimization of microneedle-based skin patch for rapid transdermal delivery of naloxone for opioid overdose treatment
Naloxone, an FDA-approved opioid inhibitor, used to reverse opioid overdose complications has up till date faced challenges associated with its delivery. Limitations include the use of invasive delivery forms and the need for frequent redosing due to its short half-life. The goal of the current study was to design a transdermal rapidly dissolving polymeric microneedle (MN) patch with delivery and pharmacokinetic properties comparable to that seen with the commercially available NAL products, eliminating their delivery limitations. Patches of varying dimensions (500 µm; 100 array,800 µm; 100array, and 600 µm; 225 array) were fabricated to evaluate the effect of increasing MN length, and density (no. of needles/unit area) on drug release. Drug dose in each of these patches was 17.89 ± 0.23 mg, 17.2 ± 0.77 mg, and 17.8 ± 1.01 mg, respectively. Furthermore, the insertion efficiency of each of the MN patches was 94 ± 4.8%, 90.6 ± 1.69%, and 96 ± 1.29%, respectively. Compared to passive permeation, a reduced lag time of about 5–15 min was observed with a significant drug flux of 15.09 ± 7.68 g\(\mu\)/cm2/h seen in the first 1 h (p < 0.05) with the array of 100 needles (500 µm long). Over 24 h, a four and ten-fold increase in permeation was seen with the longer length and larger density MN patch, respectively, when compared to the 500 µm (100 array) patch. Model simulations and analyses revealed the significance of needle base diameter and needle count in improving systemic pharmacokinetics of NAL. Graphical abstract- 25 July 2022
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 13 (1) , 320-338
Mechanistic modeling-guided optimization of microneedle-based skin patch for rapid transdermal delivery of naloxone for opioid overdose treatment
Naloxone, an FDA-approved opioid inhibitor, used to reverse opioid overdose complications has up till date faced challenges associated with its delivery. Limitations include the use of invasive delivery forms and the need for frequent redosing due to its short half-life. The goal of the current study was to design a transdermal rapidly dissolving polymeric microneedle (MN) patch with delivery and pharmacokinetic properties comparable to that seen with the commercially available NAL products, eliminating their delivery limitations. Patches of varying dimensions (500 µm; 100 array,800 µm; 100array, and 600 µm; 225 array) were fabricated to evaluate the effect of increasing MN length, and density (no. of needles/unit area) on drug release. Drug dose in each of these patches was 17.89 ± 0.23 mg, 17.2 ± 0.77 mg, and 17.8 ± 1.01 mg, respectively. Furthermore, the insertion efficiency of each of the MN patches was 94 ± 4.8%, 90.6 ± 1.69%, and 96 ± 1.29%, respectively. Compared to passive permeation, a reduced lag time of about 5–15 min was observed with a significant drug flux of 15.09 ± 7.68 g\(\mu\)/cm2/h seen in the first 1 h (p < 0.05) with the array of 100 needles (500 µm long). Over 24 h, a four and ten-fold increase in permeation was seen with the longer length and larger density MN patch, respectively, when compared to the 500 µm (100 array) patch. Model simulations and analyses revealed the significance of needle base diameter and needle count in improving systemic pharmacokinetics of NAL. Graphical abstract